# OnCo record paper-admiral-gilteritinib-flt3-nejm-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-admiral-gilteritinib-flt3-nejm-2019" ;
  schema:name "ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia"@en ;
  schema:description "An oral FLT3 inhibitor extended survival compared with salvage chemotherapy in relapsed AML with a FLT3 mutation, doubling the remission rate."@en ;
  schema:url <https://onco.cc/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1902688>, <https://clinicaltrials.gov/study/NCT02421939> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1902688> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Perl AE, Martinelli G, Cortes JE, et al." ;
  onco:related <https://onco.cc/key-papers/paper-quantum-first-quizartinib-lancet-2023/> ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:targets <https://onco.cc/targets/flt3/> ;
  onco:drugs <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/midostaurin/>, <https://onco.cc/drugs/quizartinib/> ;
  onco:companies <https://onco.cc/companies/astellas/> ;
  onco:terms <https://onco.cc/terms/os/> ;
  onco:trials <https://onco.cc/trials/admiral/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/> ;
  onco:journals <https://onco.cc/journals/nejm/> .